Company · CIK 0001682639 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
HYPERION DEFI, INC. · HYPD
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2026 FForm 4 → | Aug 18, 5:00 pm EDT | Hyunsu JungSee Remarks, Director | 40,000 | — | — | 1,345,676 | — | |
| Jun 30, 2026 AForm 4 → | Jul 1, 4:02 pm EDT | Happy David WaltersDirector | 58,917 | — | — | 170,847 | — | |
| Jun 30, 2026 AForm 4 → | Jul 1, 4:02 pm EDT | Ellen R StrahlmanDirector | 58,917 | — | — | 150,078 | — | |
| Jun 30, 2026 AForm 4 → | Jul 1, 4:01 pm EDT | Rachel JacobsonDirector | 58,917 | — | — | 115,218 | — | |
| Jun 30, 2026 AForm 4 → | Jul 1, 4:01 pm EDT | Michael S GeltzeilerDirector | 58,917 | — | — | 146,932 | — | |
| Jan 2, 2019 MForm 4 → | Jan 3, 5:29 pm EST | Curt H LaBelleDirector, 10% Owner | 140,000 | $1.24 | $173,600 | 606,667 | — | plan? |
| Jan 2, 2019 MForm 4 → | Jan 3, 5:28 pm EST | Tsontcho IanchulevChief Executive Officer, Director, 10% Owner | 313,686 | $1.54 | $483,888 | 606,667 | — | plan? |
| Sep 24, 2018 PForm 4 → | Sep 26, 5:21 pm EDT | Michael M RoweVice President of Marketing | 800 | $4.23 | $3,380 | 1,000 | +400% | plan? |
| Sep 18, 2018 PForm 4 → | Sep 20, 4:17 pm EDT | Charles E Mather IVDirector | 4,000 | $4.79 | $19,140 | 8,033 | +99.2% | plan? |
| Sep 10, 2018 MForm 4 → | Sep 18, 4:45 pm EDT | Jennifer G ClasbyVP, Clinical Operations | 28,965 | $1.95 | $56,482 | 28,965 | — | plan? late |
| Jul 24, 2018 AForm 4 → | Jul 30, 5:20 pm EDT | Anthony Y SunDirector | 4,033 | — | — | 4,033 | — | plan? late |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Ernest MarioDirector | 4,033 | — | — | 146,770 | — | plan? |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Kenneth B Lee Jr.Director | 4,033 | — | — | 4,033 | — | plan? |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Charles E Mather IVDirector | 4,033 | — | — | 4,033 | — | plan? |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Fredric N EshelmanDirector, 10% Owner | 4,033 | — | — | 1,277,461 | — | plan? |
| Jun 28, 2018 PForm 4 → | Jul 2, 4:06 pm EDT | John P GandolfoChief Financial Officer | 2,000 | $5.86 | $11,720 | 2,000 | — | plan? |
| Jun 28, 2018 PForm 4 → | Jul 2, 4:05 pm EDT | Tsontcho IanchulevChief Executive Officer, Director, 10% Owner | 6,000 | $6.63 | $39,780 | 6,000 | — | plan? |
| Jan 29, 2018 PForm 4 → | Feb 9, 10:34 am EST | Shuhei YoshidaDirector, 10% Owner | 100,000 | $10.00 | $1,000,000 | 1,718,566 | +6.18% | plan? late |
| Jan 29, 2018 PForm 4 → | Feb 9, 10:25 am EST | Senju Pharmaceutical Co., Ltd.10% Owner | 100,000 | $10.00 | $1,000,000 | 1,718,566 | +6.18% | plan? late |
| Jan 29, 2018 PForm 4 → | Feb 8, 3:37 pm EST | Curt H LaBelleDirector, 10% Owner | 10,000 | $10.00 | $100,000 | 10,000 | — | plan? late |
| Jan 29, 2018 PForm 4 → | Feb 6, 10:04 am EST | Tsontcho IanchulevChief Executive Officer, Director, 10% Owner | 10,000 | $10.00 | $100,000 | 18,749 | +114% | plan? late |
| Jan 29, 2018 PForm 4 → | Feb 6, 10:00 am EST | Fredric N EshelmanDirector, 10% Owner | 335,000 | $10.00 | $3,350,000 | 1,273,428 | +35.7% | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2019 MForm 4 → | Jan 3, 5:29 pm EST | Curt H LaBelleDirector, 10% Owner | 140,000 | — | — | 140,000 | — | |
| Jan 2, 2019 MForm 4 → | Jan 3, 5:28 pm EST | Tsontcho IanchulevChief Executive Officer, Director, 10% Owner | 313,686 | — | — | 140,000 | — | |
| Sep 10, 2018 MForm 4 → | Sep 18, 4:45 pm EDT | Jennifer G ClasbyVP, Clinical Operations | 28,965 | — | — | 51,247 | — | late |
| Jul 24, 2018 AForm 4 → | Jul 30, 5:20 pm EDT | Anthony Y SunDirector | 4,465 | — | — | 4,465 | — | late |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Ernest MarioDirector | 4,465 | — | — | 4,465 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Kenneth B Lee Jr.Director | 4,465 | — | — | 4,465 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Charles E Mather IVDirector | 4,465 | — | — | 4,465 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 6:12 pm EDT | Fredric N EshelmanDirector, 10% Owner | 4,465 | — | — | 4,655 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 5:34 pm EDT | Luke ClausonVP, Research and Development | 19,874 | — | — | 19,874 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 5:33 pm EDT | Jennifer G ClasbyVP, Clinical Operations | 19,874 | — | — | 19,874 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 5:33 pm EDT | John P GandolfoChief Financial Officer | 24,842 | — | — | 24,842 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 5:33 pm EDT | Michael M RoweVice President of Marketing | 19,874 | — | — | 19,874 | — | |
| Jul 24, 2018 AForm 4 → | Jul 26, 5:33 pm EDT | Tsontcho IanchulevChief Executive Officer, Director, 10% Owner | 124,210 | — | — | 124,210 | — | |
| Jul 2, 2018 AForm 4 → | Jul 3, 2:14 pm EDT | Michael M RoweVice President of Marketing | 60,000 | — | — | 60,000 | — | |
| Apr 16, 2018 AForm 4 → | Apr 18, 4:33 pm EDT | John P GandolfoChief Financial Officer | 71,200 | — | — | 71,200 | — |